Critical Analysis: BioStem Technologies (OTCMKTS:BSEM) versus Keros Therapeutics (NASDAQ:KROS)

BioStem Technologies (OTCMKTS:BSEM) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation and Earnings

This table compares BioStem Technologies and Keros Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioStem Technologies	$47.48 million	1.83	-$7.13 million	($0.42)	-12.22
Keros Therapeutics	$244.06 million	0.90	$87.01 million	$1.82	6.15

Keros Therapeutics has higher revenue and earnings than BioStem Technologies. BioStem Technologies is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioStem Technologies and Keros Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioStem Technologies	N/A	N/A	N/A
Keros Therapeutics	35.65%	14.25%	13.27%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BioStem Technologies and Keros Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioStem Technologies	0	1	0	0	2.00
Keros Therapeutics	1	4	4	0	2.33

Keros Therapeutics has a consensus price target of $21.33, indicating a potential upside of 90.48%. Given Keros Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than BioStem Technologies.

Insider & Institutional Ownership

71.6% of Keros Therapeutics shares are held by institutional investors. 22.9% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Keros Therapeutics beats BioStem Technologies on 12 of the 13 factors compared between the two stocks.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

About Keros Therapeutics

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.